Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Non-Current Assets for 6 consecutive years, with $593000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 65.12% to $593000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $593000.0 through Dec 2025, down 65.12% year-over-year, with the annual reading at $593000.0 for FY2025, 65.12% down from the prior year.
  • Other Non-Current Assets hit $593000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $1.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $29.7 million in Q4 2021 to a low of $97000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $2.4 million across 5 years, with a median of $1.1 million in 2025.
  • Biggest YoY gain for Other Non-Current Assets was 1652.58% in 2022; the steepest drop was 98.75% in 2022.
  • Year by year, Other Non-Current Assets stood at $29.7 million in 2021, then tumbled by 98.75% to $371000.0 in 2022, then soared by 358.22% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then plummeted by 65.12% to $593000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for IMDX at $593000.0 in Q4 2025, $1.5 million in Q3 2025, and $1.7 million in Q2 2025.